To order this 190+ page report, which features 200+ figures and 30+ tables, please visit https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html
Key Inclusions
- A detailed review of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), type of drug, biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous), type of therapy (monotherapy and combination therapy) and dosing frequency. In addition, it includes a list of next generation complement therapeutics with special designations. Further, the chapter presents a list of players developing next generation complement therapeutics along with information on their year of establishment, company size and location of headquarters.
- Presently, 190+ complement therapeutics have been marketed / are being evaluated across different phases of development for the treatment of various disease indications
- Close to 80% of the pipeline candidates are under clinical evaluation. Further, therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO®, have been approved for the treatment of Hereditary Angioedema. Majority (84%) of these candidates are biologics, followed by small molecules (16%).
- Around 50 industry and non-industry players are engaged in the development of next generation complement therapy
- Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
- An in-depth analysis of completed, ongoing and planned clinical studies of various next generation complement therapeutics, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
- A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, which have been published during 2017-2021, based on parameters, such as year of publication, emerging focus areas, top authors, key research journals, popular indication(s) and therapeutic area(s).
- An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021, on the basis of parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section, type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.
- An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
- An analysis of the partnerships that have been established in this domain since 2014, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, product distribution and commercialization agreement, research and development agreement, and research, development and commercialization agreement and other relevant types of deals.
- A detailed analysis of the various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.
- An analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
- Target Disease Indication
- Atypical Hemolytic Uremic Syndrome
- Cardiac Transplantation Rejection
- Cold Agglutinin Disease
- COVID-19
- Generalized Myasthenia Gravis
- Guillain-Barre Syndrome
- Hereditary Angioedema
- Neuromyelitis Optica
- Paroxysmal Nocturnal Hemoglobinuria
- Therapeutic Area
- Cardiovascular Disorders
- Genetic Disorders
- Hematological and Vascular Disorders
- Infectious Diseases
- Neurological Disorders
- Neuromuscular Disorders
- Type of Molecule
- Biologic
- Small Molecule
- Target Pathway
- Alternate Pathway
- Classical Pathway
- Lectin Pathway
- Terminal Pathway
- Type of Therapy
- Monotherapy
- Combination Therapy
- Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
To request sample pages, please visit https://www.rootsanalysis.com/reports/next-generation-complement-therapeutics-market.html
Key Questions Answered
- Who are the leading industry and non-industry players engaged in the development of next generation complement therapeutics?
- Which are the key drugs being developed across early and late stages of development?
- Which geographies are the most active in conducting clinical trials related to next generation complement therapeutics?
- What is the focus area of various publications related to the next generation complement therapeutics?
- Which are the leading funding institutes / centers supporting the research related to next generation complement therapeutics?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Who are the key investors, active in the field of next generation complement therapeutics?
- What are the different initiatives undertaken by big pharma players for the development of next generation complement therapeutics in the recent past?
- How is the current and future market opportunity, related to next generation complement therapeutics likely to be distributed across key market segments?
You may also be interested in the following titles:
- Gene Editing beyond CRISPR Market, 2022-2035
- Myeloid Cells Targeting Therapeutics Market, 2021-2035
- Thermostable Vaccines and Thermostable Biologics Market, 2021-2035
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
Quora – https://rootsanalysisinsights.quora.com/
